{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:07Z","timestamp":1761870307481,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.026","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T23:49:29Z","timestamp":1305935369000},"page":"S82-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Management of Myeloma: An Italian Perspective"],"prefix":"10.1016","volume":"11","author":[{"given":"Benedetto","family":"Bruno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2005","series-title":"Cancer Facts and Figures 2005","key":"10.1016\/j.clml.2011.03.026_bib1"},{"key":"10.1016\/j.clml.2011.03.026_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdi098","article-title":"Cancer incidence and mortality in Europe, 2004","volume":"16","author":"Boyle","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.026_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: Proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.026_bib7","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib8","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib10","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib11","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo","volume":"113","author":"Bruno","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib12","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2008-07-170746","article-title":"Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting","volume":"113","author":"Rotta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly-diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib14","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib15","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib16","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib17","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2011.03.026_bib18","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2011.03.026_bib22","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib23","first-page":"2615","article-title":"Proteasome Inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.03.026_bib24","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib25","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.03.026_bib26","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib29","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.026_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3816\/CLML.2010.n.068","article-title":"Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials","volume":"10","author":"Offidani","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2011.03.026_bib32","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib33","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once weekly bortezomib in multiple myeloma patients","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib34","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexametasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib35","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib36","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.026_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"issue":"suppl; abstr 3593","key":"10.1016\/j.clml.2011.03.026_bib38","article-title":"Thalidomide combinations improve response rates; results from the MRC IX study","volume":"110","author":"Morgan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib39","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib41","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III Trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib43","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"suppl; abstr 15","key":"10.1016\/j.clml.2011.03.026_bib44","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study","volume":"28","author":"Moreau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib46","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.026_bib48","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib49","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.026_bib50","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib51","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib52","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2014Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib54","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib55","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib56","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"suppl s2; abstr S7b.5","key":"10.1016\/j.clml.2011.03.026_bib57","first-page":"41","article-title":"Thalidomide improves survival when used following ASCT","volume":"92","author":"Spencer","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.03.026_bib58","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"suppl; abstr 656","key":"10.1016\/j.clml.2011.03.026_bib59","article-title":"Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX Maintenance Randomisation","volume":"112","author":"Morgan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.026_bib60","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.026_bib61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10428194.2010.529207","article-title":"Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma","volume":"52","author":"Hasskarl","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"suppl; abstr 310","key":"10.1016\/j.clml.2011.03.026_bib62","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02","volume":"116","author":"Attal","year":"2010","journal-title":"Blood"},{"issue":"suppl; abstr 37","key":"10.1016\/j.clml.2011.03.026_bib63","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood"},{"issue":"suppl; abstr 622","key":"10.1016\/j.clml.2011.03.026_bib64","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients > 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:41Z","timestamp":1761870101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":64,"alternative-id":["S2152265011000401"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.026","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Myeloma: An Italian Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}